Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is an in vivo genome-editing company developing genetic medicines for patients with genetically driven diseases. Its wholly owned lead program, MGX-001, is designed as a one-time treatment for hemophilia A, using genome editing to insert a factor VIII gene into liver cells;… From the company’s description.
Over the twelve months to Jun 30, 2026, Metagenomi Therapeutics, Inc. reported revenue of $13.56M, down 59.8% from a year earlier, and a net loss of $93.46M. Its operating margin was −741.6%, and operations used $85.49M in cash. In fiscal 2025, it reported revenue of $25.21M, down 51.8% from fiscal 2024, and a net loss of $87.87M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Metagenomi Therapeutics, Inc. does
In the company’s own words
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is an in vivo genome-editing company developing genetic medicines for patients with genetically driven diseases. Its wholly owned lead program, MGX-001, is designed as a one-time treatment for hemophilia A, using genome editing to insert a factor VIII gene into liver cells; the company is also evaluating this system for other secreted protein deficiencies. Its partnered programs with Ionis target cardiometabolic diseases and aim to reduce disease-associated proteins through gene knockout. Metagenomi’s technologies include programmable nucleases, base editors, RNA-mediated integration systems and DNA-mediated integration systems, discovered using metagenomics and enhanced with machine learning and artificial intelligence. It has generated more than 20,000 signature gene-editing systems from its proprietary metagenomics database. The company focuses on research and development and does not describe reportable business segments. Its history includes regaining rights to its base-editing and RNA-mediated integration technologies after ending its Moderna collaboration in 2024, followed by a 2025 strategic reprioritization around MGX-001 and later-stage preclinical programs. Its website is https://ir.metagenomi.co/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- EMERYVILLE, CA
- Fiscal year end
- December
- CIK
- 1785279
- SIC
- 2836
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Metagenomi Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Metagenomi Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Metagenomi Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Metagenomi Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Metagenomi Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”